1. Home
  2. RYTM vs ROAD Comparison

RYTM vs ROAD Comparison

Compare RYTM & ROAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ROAD
  • Stock Information
  • Founded
  • RYTM 2008
  • ROAD 2001
  • Country
  • RYTM United States
  • ROAD United States
  • Employees
  • RYTM N/A
  • ROAD N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ROAD Engineering & Construction
  • Sector
  • RYTM Health Care
  • ROAD Industrials
  • Exchange
  • RYTM Nasdaq
  • ROAD Nasdaq
  • Market Cap
  • RYTM 3.8B
  • ROAD 3.9B
  • IPO Year
  • RYTM 2017
  • ROAD 2018
  • Fundamental
  • Price
  • RYTM $57.38
  • ROAD $95.75
  • Analyst Decision
  • RYTM Strong Buy
  • ROAD Buy
  • Analyst Count
  • RYTM 12
  • ROAD 4
  • Target Price
  • RYTM $75.42
  • ROAD $91.00
  • AVG Volume (30 Days)
  • RYTM 671.0K
  • ROAD 452.5K
  • Earning Date
  • RYTM 05-07-2025
  • ROAD 05-09-2025
  • Dividend Yield
  • RYTM N/A
  • ROAD N/A
  • EPS Growth
  • RYTM N/A
  • ROAD N/A
  • EPS
  • RYTM N/A
  • ROAD 1.13
  • Revenue
  • RYTM $136,863,000.00
  • ROAD $2,189,187,000.00
  • Revenue This Year
  • RYTM $43.84
  • ROAD $51.05
  • Revenue Next Year
  • RYTM $65.62
  • ROAD $11.65
  • P/E Ratio
  • RYTM N/A
  • ROAD $84.04
  • Revenue Growth
  • RYTM 48.88
  • ROAD 31.49
  • 52 Week Low
  • RYTM $35.17
  • ROAD $51.63
  • 52 Week High
  • RYTM $68.58
  • ROAD $103.69
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 43.00
  • ROAD 73.66
  • Support Level
  • RYTM $62.69
  • ROAD $88.88
  • Resistance Level
  • RYTM $65.53
  • ROAD $91.84
  • Average True Range (ATR)
  • RYTM 3.04
  • ROAD 3.62
  • MACD
  • RYTM -0.73
  • ROAD 1.33
  • Stochastic Oscillator
  • RYTM 1.14
  • ROAD 92.46

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About ROAD Construction Partners Inc.

Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.

Share on Social Networks: